Article
Ophthalmology
Maite Sainz de la Maza, Ines Hernanz, Aina Moll-Udina, Marina Mesquida, Alfredo Adan, Jose Antonio Martinez, Gerard Espinosa, Victor Llorenc
Summary: This study evaluated the clinical characteristics and therapeutic outcomes of patients with recurrent scleritis of unknown origin and positive QuantiFERON-TB Gold In-Tube test (QFT). The results showed that presumed TB-related scleritis may occur in patients with prior uveitis and/or concomitant uveitis or peripheral keratitis and may be triggered by previous ocular surgery. ATT treatment, sometimes combined with systemic corticosteroids and methotrexate, was effective in achieving complete remission in the majority of patients.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2023)
Review
Geriatrics & Gerontology
Nicholas Fuggle, Nasser Al-Daghri, Olivier Bock, Jaime Branco, Olivier Bruyere, Enrique Casado, Etienne Cavalier, Bernard Cortet, Maarten de Wit, Andrea Giusti, Philippe Halbout, Nicholas C. Harvey, Mickael Hiligsmann, Jean-Marc Kaufman, Andreas Kurth, Stefania Maggi, Radmila Matijevic, Salvatore Minisola, Santiago Palacios, Regis Pierre Radermecker, Friederike Thomasius, Sansin Tuzun, Nicola Veronese, John A. Kanis, Jean-Yves Reginster, Rene Rizzoli, Cyrus Cooper
Summary: Oral bisphosphonates are important in the treatment of osteoporosis, but poor adherence is a problem. New formulations aim to improve tolerance and adherence, potentially leading to better fracture outcomes.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Review
Medicine, General & Internal
Ken Fukuda, Tomoka Mizobuchi, Isana Nakajima, Tatsuma Kishimoto, Yusaku Miura, Yoshinori Taniguchi
Summary: Relapsing polychondritis (RPC) is a rare systemic immune-mediated disease characterized by recurrent inflammation of cartilaginous and proteoglycan-rich tissues. Ocular tissues are also targets of inflammation in RPC, affecting approximately half of the patients. Physicians should be vigilant of RPC when encountering patients with recurrent ocular inflammation and various systemic symptoms.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Dentistry, Oral Surgery & Medicine
Joseph Katz, Ilan Rotstein
Summary: The prevalence of periapical lesions is significantly higher in osteoporotic patients. Patients treated with BPs showed a marked reduction in the prevalence of periapical lesions, especially when risedronate was used.
JOURNAL OF ENDODONTICS
(2021)
Review
Ophthalmology
Nicholas A. Chartrand, Chap-Kay Lau, Mark T. Parsons, Jaiden J. Handlon, Yasmyne C. Ronquillo, Phillip C. Hoopes, Majid Moshirfar
Summary: In rare cases, bisphosphonates can cause ocular inflammation, especially the second- and third-generation amino bisphosphonates. Symptoms usually resolve after discontinuation of the drug and anti-inflammatory treatment, but may recur if rechallenged with the same bisphosphonate. The mechanism of bisphosphonate-induced ocular inflammation may be related to the activation of gamma/delta T cells or M1 macrophages. Intravenous forms of bisphosphonates tend to have higher rates and faster onset of ocular inflammation compared to oral forms.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
(2023)
Review
Immunology
Weidong Zhang, Ling Gao, Wenhao Ren, Shaoming Li, Jingjing Zheng, Shasha Li, Chunmiao Jiang, Shuying Yang, Keqian Zhi
Summary: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug effect, with hypotheses involving reduced bone remodeling, infection, inflammation, and bisphosphonates-induced immune dysfunction. Treatment with bisphosphonates disrupts mucosal and osteo immune homeostasis, impairing the body's ability to resist infection and repair from injury, contributing to the development of MRONJ.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yu-Chun Chang, Junlang Li, Gabriel Mirhaidari, Jacob Zbinden, Jenny Barker, Kevin Blum, James Reinhardt, Cameron Best, John Kelly, Toshihiro Shoji, Tai Yi, Christopher Breuer
Summary: Zoledronate treatment in tissue-engineered vascular grafts (TEVGs) showed a positive effect on neotissue formation, reduced macrophage infiltration, and affected collagen deposition. It may offer a potential approach to mitigate TEVG stenosis.
Review
Ophthalmology
Ali Nouraeinejad
Summary: Patients taking bisphosphonates may experience ocular inflammation, which is a serious sight-threatening side effect that should be taken seriously. Early identification and timely treatment are crucial.
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2023)
Review
Ophthalmology
Omer Gendelman, Liana Shkolnik, Iris Vered, Merav Lidar
Summary: BROSE is a rare complication of bisphosphonate therapy, occurring more commonly in female patients with a median age of around 69 years. The most common indication for bisphosphonate treatment in these patients is osteoporosis. Most patients present with uveitis, with onset typically within 10 days of initiating bisphosphonate treatment or 2 weeks to 3 years later. There is an association between BROSE and concurrent thyroid disease or autoimmune predisposition.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Article
Ophthalmology
P. A. U. L. I. N. A. Liberman, Bryn M. Burkholder, Jennifer E. Thorne, Meghan K. Berkenstock
Summary: This study retrospectively analyzed the clinical efficacy and side effects of difluprednate therapy in patients with anterior scleritis. The results showed that difluprednate alone can effectively treat non-infectious anterior scleritis with tolerable side effects.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Endocrinology & Metabolism
Friederike Thomasius, Santiago Palacios, Asif Alam, Mitra Boolell, Francis Vekeman, Genevieve Gauthier
Summary: Patients with osteoporosis who were prescribed risedronate gastro-resistant had a lower incidence of fractures compared to those prescribed other oral bisphosphonates. Risedronate gastro-resistant does not require fasting for administration, which may contribute to its improved efficacy. The study compared fracture rates between women with osteoporosis treated with risedronate GR versus other oral bisphosphonates, showing a lower incidence of fractures in the former group.
OSTEOPOROSIS INTERNATIONAL
(2022)
Review
Medicine, General & Internal
Veronique Promelle, Vincent Goeb, Julie Gueudry
Summary: Episcleritis and scleritis are common ocular inflammatory manifestations of rheumatoid arthritis, with treatment typically involving NSAIDs, steroids, and DMARDs, with the option of using anti-TNF biologic agents for refractory cases. Close collaboration between rheumatologists/internists and ophthalmologists is essential, especially when scleritis may indicate underlying rheumatoid vasculitis.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Ahmad Abdel-Aty, Ninani Kombo
Summary: The study identified factors associated with the resolution of acute scleritis, including the use of NSAIDs, Hispanic race, and lupus erythematosus. The study also found that TNF-alpha inhibitors, NSAID use, lupus erythematosus, and Hispanic race were significantly positively associated with steroid sparing resolution. Future prospective studies are needed to further elucidate the relationship between these factors and patient outcomes.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2022)
Review
Ophthalmology
Maria Tarsia, Carla Gaggiano, Elisa Gessaroli, Salvatore Grosso, Gian Marco Tosi, Bruno Frediani, Luca Cantarini, Claudia Fabiani
Summary: Posterior idiopathic scleritis is the most common type of scleritis observed in childhood, but anterior and necrotizing inflammatory scleritis can also occur. While less common than in adults, systemic disorders can be associated with scleral inflammation in children and should be promptly recognized and treated to prevent complications. A multidisciplinary diagnostic work-up is necessary to rule out infectious and autoimmune causes and tailor treatment to the specific patient.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Clinical Neurology
Lucie Lefeuvre, Anna Caruso, Emmanuel Biver, Damien Fayolle
Summary: This article reports a case of orbital myositis triggered by alendronate. Diagnostic tests including magnetic resonance imaging and blood sample analyses were performed, and the symptoms were relieved after treatment. This case highlights the potential link between alendronate and orbital myositis, emphasizing the importance of early diagnosis.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)